Summary
For Year 2026-27, Lincoln Pharmaceuticals reports the following shareholding: Total Promoters at 49.78%, Mutual Fund at 0%, Insurance at 0%, Foreign Institutional Investors at 5.2%, Domestic Institutional Investors at 1.08%, and Retail at 43.94%. This breakdown provides a quick snapshot of ownership distribution for Lincoln Pharmaceuticals in 2026-27.
Lincoln Pharmaceuticals FAQs
As of 04-2026, the promoter shareholding in Lincoln Pharmaceuticals stands at 49.78% of the company's total shares. Promoter shareholding represents the ownership stake held by the company's founding members, management, or controlling entities, having a significant influence on the company's strategic direction and operations.
The FII and DII shareholding of Lincoln Pharmaceuticals is 5.2% and 1.08% respectively.
The retail shareholding of the Lincoln Pharmaceuticals is 43.94%.
Changes in shareholding patterns of Lincoln Pharmaceuticals can result from stock market transactions, issuance of new shares, buybacks, mergers, acquisitions, or changes in promoter holdings.
Shareholding patterns of Lincoln Pharmaceuticals are updated quarterly as mandated by regulatory authorities and may also be disclosed during significant corporate events.
The latest shareholding pattern is available on stock exchanges (e.g., NSE, BSE) and the company's official website under investor relations.
Lincoln Pharmaceuticals Associated Pages
- Lincoln Pharmaceuticals Share Price
- Lincoln Pharmaceuticals Share Price chart
- Lincoln Pharmaceuticals Fundamental Analysis
- Lincoln Pharmaceuticals Technical Analysis
- Lincoln Pharmaceuticals Peer Comparison
- Lincoln Pharmaceuticals Share Price History
- Lincoln Pharmaceuticals Dividend
- Lincoln Pharmaceuticals Board of Directors
